{"id":"CHEMBL1096562","canonicalSmiles":"COC(=O)CCC(=O)CN","inchiKey":"YUUAYBAIHCDHHD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METHYL AMINOLEVULINATE","yearOfFirstApproval":2004,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Metvix"],"synonyms":["Methyl 5-aminolevulinate","Methyl aminolaevulinate","Methyl aminolevulinate","Methyl-5-aminolevulinate"],"crossReferences":{"PubChem":["104171381"],"Wikipedia":["Methyl_aminolevulinate"],"drugbank":["DB00992"],"chEBI":["724125"]},"childChemblIds":["CHEMBL1201093"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for neoplasm and glioma and has 9 investigational indications."}
{"id":"CHEMBL1098659","canonicalSmiles":"O","inchiKey":"XLYOFNOQVPJJNP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"WATER","yearOfFirstApproval":2011,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Pur-wash","Sterile water","Sterile water for injection"],"synonyms":["Adelheid aqua","Adelheidsquelle","Aqua adelheid","Aqua pro injectione","Aqua purificata","Aqua sterilisata pro injectione","Aqua wiesbaden","Aqua wildbad","B1217","NSC-147337","Purified water","R-718","Sterile purified water","Sterile water for inhalation","Sterile water for injection","Sterile water for injections","Sterile water for irrigation","Ultrex ii ultrapure","Water","Water for hemodialysis","Water for inhalation, sterile","Water for injection","Water for injections","Water for irrigation,sterile","Water purified","Water, deionized","Water, purified","Water, purified sterile","Water, sterile purified","Water,bacteriostatic","Water,bacteriostatic injection","Water,deionized","Water,distilled","Water,purified","Water,sanitized","Water,sterile","Wiesbaden","Wiesbaden aqua","Wildbad aqua"],"crossReferences":{"DailyMed":["purified%20water","sterile%20water%20for%20irrigation"],"Wikipedia":["Properties_of_water"],"drugbank":["DB09145"],"chEBI":["15377"]},"childChemblIds":["CHEMBL2105800","CHEMBL1232306","CHEMBL2106489"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for primary short bowel syndrome and multiple sclerosis and has 23 investigational indications."}
{"id":"CHEMBL1162545","canonicalSmiles":"O=CC(=O)O","inchiKey":"HHLFWLYXYJOTON-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GLYOXYLATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2-Oxoacetate"],"crossReferences":{"Wikipedia":["Glyoxylic_acid"],"drugbank":["DB04343"],"chEBI":["16891"]},"childChemblIds":["CHEMBL3986754"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1165","canonicalSmiles":"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O","inchiKey":"UWWDHYUMIORJTA-HSQYWUDLSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MOEXIPRIL","yearOfFirstApproval":1995,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Moexipril","RS-10085","Uniretic","Univasc"],"crossReferences":{"DailyMed":["moexipril%20hydrochloride"],"Wikipedia":["Moexipril"],"drugbank":["DB00691"],"chEBI":["6960"]},"childChemblIds":["CHEMBL1200534"],"linkedTargets":{"rows":["ENSG00000159640"],"count":1},"linkedDiseases":{"rows":["EFO_0000319","EFO_1001486","EFO_0000537"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for cardiovascular disease and hypertension and has 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1194287","canonicalSmiles":"CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1","inchiKey":"ICKFFNBDFNZJSX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHLOROPYRAMINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Chloropyramine","Halopyramine","NSC-241038"],"crossReferences":{"PubChem":["11112580","174007197","50100492"],"drugbank":["DB08800"]},"childChemblIds":["CHEMBL550011"],"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL119489","canonicalSmiles":"CN(C)c1cccc2c(S(N)(=O)=O)cccc12","inchiKey":"TYNBFJJKZPTRKS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL119489","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02866"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1201050","canonicalSmiles":"Cc1cccn2c(=O)c(-c3nnn[n-]3)cnc12.[K+]","inchiKey":"NMMVKSMGBDRONO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PEMIROLAST POTASSIUM","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201198","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alamast"],"synonyms":["Alegysal","BMY-26517","Pemirolast potassium","Pemirolast potassium salt","Permirolast potassium"],"crossReferences":{"PubChem":["144205991","170465431"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999."}
{"id":"CHEMBL1201087","canonicalSmiles":"C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21","inchiKey":"KORNTPPJEAJQIU-KJXAQDMKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CABERGOLINE","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cabaser","Cabergoline","Dostinex"],"synonyms":["Cabergoline","FCE 21336","FCE-21336","Velactis"],"crossReferences":{"DailyMed":["cabergoline"],"PubChem":["144206142","170464667"],"Wikipedia":["Cabergoline"],"drugbank":["DB00248"],"chEBI":["3286"]},"linkedTargets":{"rows":["ENSG00000149295"],"count":1},"linkedDiseases":{"rows":["Orphanet_64739","EFO_0002610","EFO_0000545","EFO_0001065","MONDO_0007254","EFO_1001110","EFO_0001073","EFO_1000979","MONDO_0002491","EFO_1001485","EFO_0000512","MONDO_0005180","EFO_0004270","EFO_0000400","EFO_0008516"],"count":15},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for hypothalamic neoplasm and parkinson disease and has 12 investigational indications."}
{"id":"CHEMBL1201255","canonicalSmiles":"CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1cn(Cc2ccccc2)cn1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1","inchiKey":"HHXHVIJIIXKSOE-QILQGKCVSA-N","drugType":"Protein","blackBoxWarning":false,"name":"HISTRELIN","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Supprelin"],"synonyms":["Histrelin","ORF 17070","ORF 17070RWJ 17070","ORF-17070","RWJ 17070","RWJ-17070"],"crossReferences":{"DailyMed":["histrelin%20acetate"],"Wikipedia":["Histrelin"],"chEBI":["5739"]},"childChemblIds":["CHEMBL1200509"],"linkedTargets":{"rows":["ENSG00000109163"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0009029","EFO_0000673","EFO_0000196","MONDO_0008315"],"count":5},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 3 investigational indications."}
{"id":"CHEMBL1201472","drugType":"Unknown","blackBoxWarning":false,"name":"ICODEXTRIN","yearOfFirstApproval":2002,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Extraneal"],"synonyms":["Icodextrin"],"crossReferences":{"DailyMed":["icodextrin"],"DrugCentral":["4105"],"Wikipedia":["Icodextrin"]},"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 2 investigational indications."}
{"id":"CHEMBL1201492","drugType":"Small molecule","blackBoxWarning":false,"name":"SEVELAMER HYDROCHLORIDE","yearOfFirstApproval":1998,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Renagel"],"synonyms":["GT-16-026A","GT16-026A","Sevelamer hydrochloride"],"crossReferences":{"DailyMed":["sevelamer%20hydrochloride"],"Wikipedia":["Sevelamer"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for chronic kidney disease and kidney disease and has 4 investigational indications."}
{"id":"CHEMBL1228","canonicalSmiles":"CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O","inchiKey":"HFHZKZSRXITVMK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXYPHENBUTAZONE","yearOfFirstApproval":1960,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"," United States"," Germany"," France"],"classes":["Dermatological toxicity"," Hematological toxicity"],"year":1984},"tradeNames":["Oxyphenbutazone","Tandearil"],"synonyms":["Oxyphenbutazone"],"crossReferences":{"PubChem":["144203965","170465310","26748182","56463172"],"Wikipedia":["Oxyphenbutazone"],"drugbank":["DB03585"],"chEBI":["76258"]},"childChemblIds":["CHEMBL3989676"],"linkedTargets":{"rows":["ENSG00000073756","ENSG00000095303"],"count":2},"linkedDiseases":{"rows":["HP_0002829","HP_0003326","EFO_0005755","EFO_0005752"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 4 approved indications. It was withdrawn in United Kingdom,  United States,  Germany and  France initially in 1984 due to Dermatological toxicity and  Hematological toxicity."}
{"id":"CHEMBL1229648","canonicalSmiles":"O=[N+]([O-])c1ccccc1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O","inchiKey":"KUWPCJHYPSUOFW-YBXAARCKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1229648","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["26731487"],"drugbank":["DB01920"],"chEBI":["90144"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1231840","canonicalSmiles":"[C-]#[O+]","inchiKey":"UGFAIRIUMAVXCW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CARBON MONOXIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Carbon monoxide","Carbon oxide (co)","Carboneum oxygenisatum"],"crossReferences":{"drugbank":["DB11588"],"chEBI":["17245"]},"childChemblIds":["CHEMBL2364719"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL1232142","canonicalSmiles":"Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1","inchiKey":"BYNQFCJOHGOKSS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SONECLOSAN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Hydroxydichlorodiphenyl ether","Soneclosan","Tinosan hp100"],"crossReferences":{"drugbank":["DB04393"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1232889","canonicalSmiles":"O=C(O)c1c[nH]c(-c2ccccc2)n1","inchiKey":"XCAXKZJNJCKTQH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1232889","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07803"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1237135","canonicalSmiles":"CNCCCC12CCC(c3ccccc31)c1ccccc12.Cl","inchiKey":"NZDMFGKECODQRY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MAPROTILINE HYDROCHLORIDE","yearOfFirstApproval":1980,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL21731","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ludiomil","Maprotiline hydrochloride"],"synonyms":["BA-34,276","BA-34276","Maprotiline hcl","Maprotiline hydrochloride","NSC-757085"],"crossReferences":{"PubChem":["144211309","14743087","152146163","26719700","26747580","26747581","50106647","50106648","56422491","855591"]},"linkedTargets":{"rows":["ENSG00000103546"],"count":1},"linkedDiseases":{"rows":["EFO_0003761"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for unipolar depression. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1242","canonicalSmiles":"Nc1ccc(/N=N/c2ccccc2)c(N)n1","inchiKey":"QPFYXYFORQJZEC-FOCLMDBBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENAZOPYRIDINE","yearOfFirstApproval":1987,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["NSC-145895","Phenazopyridine"],"crossReferences":{"PubChem":["104171363"],"Wikipedia":["Phenazopyridine"],"drugbank":["DB01438"]},"childChemblIds":["CHEMBL1201022"],"linkedTargets":{"rows":["ENSG00000185313","ENSG00000153253","ENSG00000183873","ENSG00000136546","ENSG00000144285","ENSG00000169432","ENSG00000168356","ENSG00000007314","ENSG00000136531","ENSG00000196876"],"count":10},"linkedDiseases":{"rows":["EFO_0003103","HP_0000016","EFO_0003901","EFO_0003843"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 4 investigational indications."}
{"id":"CHEMBL1278","canonicalSmiles":"CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1","inchiKey":"AMKVXSZCKVJAGH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NARATRIPTAN","yearOfFirstApproval":1998,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Amerge","Naratriptan"],"synonyms":["Amerge","Naratriptan"],"crossReferences":{"DailyMed":["naratriptan%20hydrochloride"],"Wikipedia":["Naratriptan"],"drugbank":["DB00952"],"chEBI":["7478"]},"childChemblIds":["CHEMBL1200601"],"linkedTargets":{"rows":["ENSG00000135312","ENSG00000179546"],"count":2},"linkedDiseases":{"rows":["MONDO_0005277","HP_0012075","EFO_0000677","HP_0002315"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for migraine disorder and has 1 investigational indication."}
{"id":"CHEMBL1297","canonicalSmiles":"CC(C(=O)O)c1cccc(Oc2ccccc2)c1","inchiKey":"RDJGLLICXDHJDY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"FENOPROFEN","yearOfFirstApproval":1976,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Progesic"],"synonyms":["53858","Fenoprofen","LILLY-53858","NSC-757813","Nalfon"],"crossReferences":{"DailyMed":["fenoprofen%20calcium"],"Wikipedia":["Fenoprofen"],"drugbank":["DB00573"],"chEBI":["5004"]},"childChemblIds":["CHEMBL2068720","CHEMBL2103736","CHEMBL138241"],"linkedTargets":{"rows":["ENSG00000073756","ENSG00000095303"],"count":2},"linkedDiseases":{"rows":["EFO_0000685","MONDO_0005178","EFO_0005755"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 3 approved indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1329203","canonicalSmiles":"CCCCC(CC)COC(=O)c1ccccc1O","inchiKey":"FMRHJJZUHUTGKE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OCTISALATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Uvinul"],"synonyms":["Escalol","Ethyl hexyl salicylate","Ethylhexyl salicylate","NSC-46151","Neo heliopan","Octisalate","Octyl salicylate"],"crossReferences":{"PubChem":["144205126","170465498","26754457","29215231"],"drugbank":["DB11062"],"chEBI":["88639"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1365576","canonicalSmiles":"Clc1ccc(Sc2cc(Cl)c(Cl)cc2Cl)cc1","inchiKey":"QUWSDLYBOVGOCW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TETRASUL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Animert","Tetrasul","V-101"],"crossReferences":{"PubChem":["144209590","144213301","29217921"],"drugbank":["DB12838"],"chEBI":["82162"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1448","canonicalSmiles":"O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O","inchiKey":"RJMUSRYZPJIFPJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NICLOSAMIDE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ex A Lint","Lintex","Niclocide","Nicloside","Yomesan"],"synonyms":["BAY 2353","BAY-2353","NSC-178296","Niclosamide","Niclosamide (anhydrous)","Niclosamide anhydrous","Niclosamide, anhydrous","Niclosamidum anhydrous","WR 46234"],"crossReferences":{"PubChem":["104171199","11111533","11111534","124880876","144203760","144211066","170465184","174006693","26747596","26753613","50100291","50106712","50106713","56463356","85231153","90341111"],"Wikipedia":["Niclosamide"],"drugbank":["DB06803"]},"childChemblIds":["CHEMBL3794255"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for helminthiasis and has 6 investigational indications."}
{"id":"CHEMBL1469","canonicalSmiles":"O=C(O)CCCc1ccccc1","inchiKey":"OBKXEAXTFZPCHS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENYLBUTANOIC ACID","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Phenylbutanoic acid","Phenylbutyrate"],"crossReferences":{"DailyMed":["sodium%20phenylbutyrate"],"PubChem":["67217","855904"],"drugbank":["DB06819"],"chEBI":["41500"]},"childChemblIds":["CHEMBL1746"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 approved and 18 investigational indications."}
{"id":"CHEMBL1516","canonicalSmiles":"CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1","inchiKey":"VTRAEEWXHOVJFV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OLMESARTAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-759810","Olmesartan","Olmesartan medoxomil impurity, olmesartan-","RNH-6270"],"crossReferences":{"PubChem":["174007156","26719844"],"Wikipedia":["Olmesartan"],"drugbank":["DB00275"],"chEBI":["48416"]},"linkedTargets":{"rows":["ENSG00000144891"],"count":1},"linkedDiseases":{"rows":["MONDO_0001134","EFO_0000275","EFO_0000712","EFO_0000407","EFO_0000537"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL1525826","canonicalSmiles":"COc1nccnc1NS(=O)(=O)c1ccc(N)cc1","inchiKey":"KXRZBTAEDBELFD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULFALENE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Kelfizina","Kelfizine w","Longum"],"synonyms":["AS-18908","NSC-110433","Sulfalene","Sulfamethopyrazine","Sulfamethoxypyrazine","Sulfametopyrazine"],"crossReferences":{"PubChem":["144205397","170465930","50086577"],"drugbank":["DB00664"],"chEBI":["32162"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for bacterial disease and has 1 investigational indication."}
{"id":"CHEMBL1630842","canonicalSmiles":"CCN1c2ncc(CCOc3cc[n+]([O-])c4ccccc34)cc2C(=O)N(C)c2cccnc21","inchiKey":"BEMBRAMZGVDPMH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BILR 355","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bilr 355"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1646","canonicalSmiles":"CC1(C)C(/C=C/C=C/C=C/C=C2\\N(CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21.[Na+]","inchiKey":"MOFVSTNWEDAEEK-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"INDOCYANINE GREEN","yearOfFirstApproval":1959,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201304","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ic-green","Indocyanine green","Spy agent green kit"],"synonyms":["Indocyanine Green","Indocyanine green","Spy agent green"],"crossReferences":{"PubChem":["144206227","57260468","57260469"],"Wikipedia":["Indocyanine_green"],"chEBI":["31696"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 19 investigational indications."}
{"id":"CHEMBL1652128","canonicalSmiles":"CC(C)(C)C(=O)OCOP(=O)(COC1(Cn2cnc3cnc(N)nc32)CC1)OCOC(=O)C(C)(C)C","inchiKey":"JLKJXDOWBVVABZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LB80380","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["An-380","Besifovir dipivoxil","LB 80380","LB-80380","Lb80380","Pmcdg dipivoxil"],"crossReferences":{"drugbank":["DB05020"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL1738797","canonicalSmiles":"CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O","inchiKey":"KDGFLJKFZUIJMX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ALECTINIB","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alecensa"],"synonyms":["AF-802","AF802","Alectinib","CH-5424802","CH5424802","RO-5424802","RO5424802"],"crossReferences":{"DailyMed":["alectinib%20hydrochloride"],"PubChem":["174006440"],"drugbank":["DB11363"]},"childChemblIds":["CHEMBL3707320"],"linkedTargets":{"rows":["ENSG00000165731","ENSG00000171094","ENSG00000143924"],"count":3},"linkedDiseases":{"rows":["EFO_0000616","EFO_0003893","EFO_1000849","EFO_0000756","MONDO_0021117","EFO_0003060","EFO_0005221","EFO_0000311","EFO_0003826","EFO_0003032","EFO_0003860","EFO_0001421","EFO_0004284","EFO_0004142","EFO_0000326","EFO_0000641","EFO_0003833","EFO_0000691","EFO_0000519"],"count":19},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 4 investigational indications."}
{"id":"CHEMBL1742471","canonicalSmiles":"N=C(N)Nc1nc(CSCCN/C=N/S(=O)(=O)c2ccc(Br)cc2)cs1","inchiKey":"ZQHFZHPUZXNPMF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EBROTIDINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["Spain"],"classes":["Hepatotoxicity"],"year":1998},"tradeNames":[],"synonyms":["Ebrotidine"],"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in Spain  in 1998 due to Hepatotoxicity."}
{"id":"CHEMBL1742986","drugType":"Protein","blackBoxWarning":false,"name":"ATACICEPT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Atacicept","TACI-FC5","TACI-IG"],"linkedTargets":{"rows":["ENSG00000161955","ENSG00000102524"],"count":2},"linkedDiseases":{"rows":["EFO_0000685","EFO_0005761","EFO_0007405","EFO_0002690","MONDO_0005301","EFO_0004194"],"count":6},"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL1783256","canonicalSmiles":"CCCNC(=O)c1nnc2c(-c3cc(OC)ccc3OC)cccc2c1N","inchiKey":"NVWCZRPXYVDQEE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZD6280","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZD6280","Azd-6280","Azd6280"],"crossReferences":{"drugbank":["DB12210"]},"linkedTargets":{"rows":["ENSG00000011677","ENSG00000151834"],"count":2},"linkedDiseases":{"rows":["EFO_0005230"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1835207","canonicalSmiles":"CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1","inchiKey":"JTMITOKKUMVWRT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"APRICOXIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Apricoxib","CS-706","R-109339","TG-01","TG01"],"crossReferences":{"drugbank":["DB12378"]},"linkedTargets":{"rows":["ENSG00000073756"],"count":1},"linkedDiseases":{"rows":["EFO_0002618","MONDO_0007254","EFO_0003060"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL1865258","canonicalSmiles":"NS(=O)(=O)c1ccc(Cl)c(S(N)(=O)=O)c1","inchiKey":"NENBAISIHCWPKP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CLOFENAMIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-chloro-m-benzenedisulfonamide","Chloramidobenzol","Clofenamide","Monochlorphenamide"],"crossReferences":{"PubChem":["144205367","170466058","81066277"],"drugbank":["DB13663"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1899506","canonicalSmiles":"CN1CCCC(=C(c2cccs2)c2cccs2)C1","inchiKey":"JWIXXNLOKOAAQT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TIPEPIDINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AT 327","AT-327","CR-662","CRJ662","Tipepidine","Tipepidine hibenzate"],"crossReferences":{"PubChem":["144205981","50112677"],"drugbank":["DB13474"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL1909286","canonicalSmiles":"CC(COc1ccccc1)NN","inchiKey":"QNEXFJFTGQBXBJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENOXYPROPAZINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"],"classes":["Hepatotoxicity"],"year":1966},"tradeNames":[],"synonyms":["Fenoxypropazine","Phenoxypropazine"],"crossReferences":{"PubChem":["144206870"],"Wikipedia":["Phenoxypropazine"],"drugbank":["DB09251"]},"childChemblIds":["CHEMBL4303424"],"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in United Kingdom  in 1966 due to Hepatotoxicity."}
{"id":"CHEMBL2105078","canonicalSmiles":"CCOC(=O)C1(c2ccccc2)CCN(CCOCC2CCCO2)CC1","inchiKey":"NNCOZXNZFLUYGG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FURETHIDINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Furethidine","IDS-NF-002"],"crossReferences":{"drugbank":["DB01464"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2106548","canonicalSmiles":"COC(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1ccc(Cl)c(Cl)c1","inchiKey":"JKXQBIZCQJLVOS-GSNLGQFWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CLOMETOCILLIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Clometocillin"],"crossReferences":{"drugbank":["DB13686"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2107065","canonicalSmiles":"CC[N+](C)(CC)CCSC1=Nc2ccccc2N=C(c2ccc(Sc3ccccc3)cc2)C1.[I-]","inchiKey":"YTSPICCNZMNDQT-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"TIBEZONIUM IODIDE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL2111016","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-308905","Tibezonium iodide"],"crossReferences":{"drugbank":["DB13702"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2107759","canonicalSmiles":"CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C","inchiKey":"GJQWFXNJAXOCBV-XVGNUGADSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MILATAXEL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MAC-321","Milataxel"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2107811","canonicalSmiles":"CO/N=C1\\CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC12CNC2","inchiKey":"ZNPOCLHDJCAZAH-OEAKJJBVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ZABOFLOXACIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Zabofloxacin"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2108210","drugType":"Small molecule","blackBoxWarning":false,"name":"LAVENDER OIL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FEMA NO. 2622","Lavandula angustifolia oil","Lavandulae aetheroleum","Lavender oil"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2108494","drugType":"Protein","blackBoxWarning":false,"name":"INTERFERON","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Interferon"],"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for eye infection and has 27 investigational indications."}
{"id":"CHEMBL2108508","drugType":"Protein","blackBoxWarning":true,"name":"INTERFERON ALFA-2A","yearOfFirstApproval":1986,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Roferon-a"],"synonyms":["INTERFERON ALFA-2A","Interferon alfa-2a","Interferon alfa-2a (genetical recombination)","RO 22-8181","RO-22-8181","RO-228181"],"linkedTargets":{"rows":["ENSG00000159110","ENSG00000142166"],"count":2},"linkedDiseases":{"rows":["EFO_0000220","EFO_0003780","EFO_0000756","EFO_0000681","EFO_0000311","EFO_0004220","EFO_1000956","EFO_0000764","EFO_0000676","EFO_0000574","MONDO_0002367","EFO_0001378","EFO_0003047","EFO_0002617","EFO_1001156"],"count":15},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 15 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2108593","drugType":"Protein","blackBoxWarning":false,"name":"EPOETIN ZETA","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Retacrit"],"synonyms":["Epoetin","Epoetin zeta","Erythropoietin","Erythropoietin for bioassays"],"crossReferences":{"DrugCentral":["5170"]},"linkedTargets":{"rows":["ENSG00000187266"],"count":1},"linkedDiseases":{"rows":["EFO_0000198","EFO_1001459"],"count":2},"description":"Protein drug with a maximum clinical trial phase of IV and has 1 investigational indication."}
{"id":"CHEMBL2108796","drugType":"Antibody","blackBoxWarning":false,"name":"MINRETUMOMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CC49","Cc-49","MAB-CC49","MOAB CC49","Minretumomab"],"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL2109412","drugType":"Antibody","blackBoxWarning":false,"name":"L19SIP 131I","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["L19SIP","L19sip 131i"],"linkedTargets":{"rows":["ENSG00000115414"],"count":1},"linkedDiseases":{"rows":["EFO_0003060","EFO_0000311"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2109433","drugType":"Antibody","blackBoxWarning":false,"name":"OTILIMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GSK-3196165","GSK3196165","MOR-103","MOR103","Mor-103","Otilimab"],"linkedTargets":{"rows":["ENSG00000164400"],"count":1},"linkedDiseases":{"rows":["EFO_0000694","EFO_0000685","MONDO_0005301","MONDO_0005178"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2109503","drugType":"Antibody","blackBoxWarning":false,"name":"LMB-9","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["B3 (DSFV) -PE (PSEUDOMONAS AERUGINOSA EXOTOXIN A)38","LMB-9","Lmb-9"],"description":"Antibody drug with a maximum clinical trial phase of I (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL2109511","drugType":"Antibody","blackBoxWarning":false,"name":"ONTAMALIMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ontamalimab","PF-00547659","Pf-00547659","SHP-647","SHP647","Shp647"],"linkedTargets":{"rows":["ENSG00000099866"],"count":1},"linkedDiseases":{"rows":["EFO_0000729","EFO_0000384"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2109635","drugType":"Antibody","blackBoxWarning":false,"name":"SAR-566658","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SAR-566658","SAR566658","Sar-566658","huDS6-DM4"],"linkedTargets":{"rows":["ENSG00000185499"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0007254"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2110753","canonicalSmiles":"CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC1=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N2","inchiKey":"GUCYBPFJNGVFEB-XELKFLSISA-N","drugType":"Protein","blackBoxWarning":false,"name":"ISEGANAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["IB-367","Iseganan"],"childChemblIds":["CHEMBL2105862"],"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2142890","canonicalSmiles":"CC(=O)NC(CCC(=O)O)C(=O)O","inchiKey":"RFMMMVDNIPUKGG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ACEGLUMATE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["93576735"]},"childChemblIds":["CHEMBL3833347"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for attention deficit hyperactivity disorder."}
{"id":"CHEMBL2204263","canonicalSmiles":"O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3cncs3)CC2)C1","inchiKey":"CFKBNYUHQSQBSX-CYWCHRQTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"JNJ-41443532","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Jnj-41443532"],"crossReferences":{"drugbank":["DB12632"]},"linkedTargets":{"rows":["ENSG00000121807"],"count":1},"linkedDiseases":{"rows":["MONDO_0005148"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2219425","canonicalSmiles":"CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21","inchiKey":"DDINXHAORAAYAD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ARIPIPRAZOLE LAUROXIL","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aristada","Aristada initio kit"],"synonyms":["ALKS 9072","ALKS-9070","ALKS-9072","Aripiprazole lauroxil","Aristada initio","RDC-3317","RDC3317"],"crossReferences":{"DailyMed":["aripiprazole%20lauroxil"],"drugbank":["DB14185"]},"linkedTargets":{"rows":["ENSG00000178394","ENSG00000149295","ENSG00000102468"],"count":3},"linkedDiseases":{"rows":["MONDO_0005090","MONDO_0002009","EFO_0004895","EFO_0003758","EFO_0009963","EFO_0005411"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL226117","canonicalSmiles":"CCCCCCCCCCCCCCCC(=O)NCC(=O)O","inchiKey":"KVTFEOAKFFQCCX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PALMITOYL GLYCINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["N-Ethanoyl-Hexadecanamide","N-Palmitoylglycine","Palmitoyl Glycine"],"crossReferences":{"drugbank":["DB03440"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL233553","canonicalSmiles":"CNS(=O)(=O)c1ccc(-c2ccc(/C=C3\\SC(=N)NC3=O)o2)cc1","inchiKey":"FJJJERLTHDXEPT-JYRVWZFOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL233553","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07533"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL234569","canonicalSmiles":"CCc1ccc(/C=C2\\SC(N[C@@H](c3ccc(F)cc3)c3nnn[nH]3)=NC2=O)o1","inchiKey":"BKZOQCGDCHOGOQ-MZLJFPOFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL234569","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08710"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL236708","canonicalSmiles":"Nc1nc(O)c2ncn(CCCCC(F)(F)P(=O)(O)O)c2n1","inchiKey":"JANQQPWTLXUSCD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL236708","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04260"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL242737","canonicalSmiles":"C[C@H]1CC[C@@H](NCc2ccc3c(c2)Cc2c(-c4ccc(C(=O)O)cc4)n[nH]c2-3)CC1","inchiKey":"MEDLHZCDTXWLOC-GSXCWMCISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL242737","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07320"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL257619","canonicalSmiles":"CO[C@H](C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1","inchiKey":"CFCUWKMKBJTWLW-BKHRDMLASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL257619","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06810"],"chEBI":["31856"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL259551","canonicalSmiles":"Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12","inchiKey":"XVECMUKVOMUNLE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FR-180204","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FR-180204"],"crossReferences":{"PubChem":["174006438"],"drugbank":["DB07794"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL267431","canonicalSmiles":"COC[C@]1(OC)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(/C=N/O)cc3)C[C@@]21C","inchiKey":"GJMNAFGEUJBOCE-MEQIQULJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ASOPRISNIL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Asoprisnil","BAY86-5294","J-867","J867"],"crossReferences":{"Wikipedia":["Asoprisnil"],"drugbank":["DB06680"]},"linkedTargets":{"rows":["ENSG00000082175"],"count":1},"linkedDiseases":{"rows":["EFO_0000731","EFO_0001065","HP_0000132","MONDO_0001572","HP_0100608","EFO_0003922"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL270190","canonicalSmiles":"C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1","inchiKey":"UPNUIXSCZBYVBB-JVFUWBCBSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ALVIMOPAN","yearOfFirstApproval":2008,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Entereg"],"synonyms":["ADL 8-2698","ADL-8-2698","Alvimopan","Alvimopan anhydrous","Alvimopan dihydrate","Anhydrous alvimopan","LY-246736","LY-246736 DIHYDRATE","LY246736"],"crossReferences":{"DailyMed":["alvimopan"],"Wikipedia":["Alvimopan"],"drugbank":["DB06274"]},"linkedTargets":{"rows":["ENSG00000112038"],"count":1},"linkedDiseases":{"rows":["MONDO_0004880","MONDO_0002158","MONDO_0008170","MONDO_0004567","MONDO_0002087","EFO_0003843","HP_0002019","MONDO_0001187"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for constipation and has 5 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL28318","canonicalSmiles":"Cc1c(C(C)C)c(=O)n(-c2ccccc2)n1C","inchiKey":"PXWLVJLKJGVOKE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PROPYPHENAZONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Isopropylantipyrine","Propyphenazone","Yoshipyrin"],"crossReferences":{"PubChem":["144205786","170465821","26758034"],"Wikipedia":["Propyphenazone"],"drugbank":["DB13524"],"chEBI":["135538"]},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL293498","canonicalSmiles":"CC(C)=CCN1Cc2cc(Cl)cc3[nH]c(=S)n(c23)C[C@@H]1C","inchiKey":"RCSLUNOLLUVOOG-NSHDSACASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"R-82913","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["R-82913"],"crossReferences":{"drugbank":["DB08598"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL295316","canonicalSmiles":"CC1=CC(=O)c2c(O)cccc2C1=O","inchiKey":"VCMMXZQDRFWYSE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PLUMBAGIN","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-236613","NSC-688284","PCUR-101","Pcur-101","Plumbagin"],"crossReferences":{"PubChem":["133894","26747815","26753709"],"Wikipedia":["Plumbagin"],"chEBI":["8273"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL297362","canonicalSmiles":"Cc1cccc(C)c1NC1=NCCCS1","inchiKey":"BPICBUSOMSTKRF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"XYLAZINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Chanazine","NSC-758142","Xylazine"],"crossReferences":{"PubChem":["104171265","11111970","11111971","124881828","144203854","170466147","26747186","26752277","3712514","90341260"],"Wikipedia":["Xylazine"],"drugbank":["DB11477"]},"childChemblIds":["CHEMBL1256022"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3039543","drugType":"Antibody","blackBoxWarning":false,"name":"ULOCUPLUMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-936564","MDX-1338","Ulocuplumab"],"linkedTargets":{"rows":["ENSG00000121966"],"count":1},"linkedDiseases":{"rows":["EFO_0000565","EFO_0009441","EFO_0000616","EFO_0000095","EFO_0000222","EFO_0001378","MONDO_0018906"],"count":7},"description":"Antibody drug with a maximum clinical trial phase of I (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL3084748","canonicalSmiles":"O=C(O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1.[Cl-]","inchiKey":"RVCSYOQWLPPAOA-QKYUOBHYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"TROSPIUM CHLORIDE","yearOfFirstApproval":2004,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1888176","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Flotros","Regurin","Regurin xl","Sanctura","Sanctura xr","Spasmo-lyt","Trospium chloride","Uraplex"],"synonyms":["IP-631","IP631","Relaspium","Spasmex","Spasmolyt","Trospium chloride"],"crossReferences":{"DailyMed":["trospium%20chloride"],"PubChem":["144205995","170464918"]},"linkedTargets":{"rows":["ENSG00000133019","ENSG00000181072"],"count":2},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0006865","EFO_1000781","EFO_0000341"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for overactive bladder and urgency urinary incontinence and has 2 investigational indications."}
{"id":"CHEMBL316257","canonicalSmiles":"CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC","inchiKey":"CITHEXJVPOWHKC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"L-Alpha-Dimyristoylphosphatidylcholine","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["L-Alpha-Dimyristoylphosphatidylcholine"],"crossReferences":{"PubChem":["144206232","50125764"],"drugbank":["DB11283"],"chEBI":["241349"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3183453","canonicalSmiles":"CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c([O-])c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C.[Na+]","inchiKey":"WWPRGAYLRGSOSU-RNROJPEYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"NOVOBIOCIN SODIUM","yearOfFirstApproval":1964,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL36506","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"],"classes":["Dermatological toxicity"," Hematological toxicity"," Hepatotoxicity"],"year":2009},"tradeNames":["Albamycin","Spheromycin","Vulcamycin"],"synonyms":["NSC-2382","Novobiocin monosodium salt","Novobiocin sodium","Novobiocin, monosodium salt","Sodium novobiocin"],"crossReferences":{"PubChem":["144204298","170465360"],"chEBI":["31924"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1964. It was withdrawn in United States  in 2009 due to Dermatological toxicity,  Hematological toxicity and  Hepatotoxicity."}
{"id":"CHEMBL325434","canonicalSmiles":"COc1ccc(OC)c(CN(C)c2ccc3nc(N)nc(N)c3c2)c1","inchiKey":"YBJANOUTWRTBDK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL325434","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02427"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL329433","canonicalSmiles":"NC(=O)c1cn([C@@H](CO)CCc2ccccc2)cn1","inchiKey":"ZUYUIKKHHBEVHL-GFCCVEGCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL329433","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02096"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL331057","canonicalSmiles":"O=C(Nc1ccc(Oc2ccc(C(=O)O)c(C(=O)O)c2)c(NC(=O)c2cccc([N+](=O)[O-])c2)c1)c1cccc([N+](=O)[O-])c1","inchiKey":"VFYAZSTYKPFSFL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL331057","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03067"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3349523","canonicalSmiles":"CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(N)=O)NC1=O","inchiKey":"SWXOGPJRIDTIRL-DOUNNPEJSA-N","drugType":"Protein","blackBoxWarning":false,"name":"CHEMBL3349523","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04894"]},"description":"Protein drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3544983","canonicalSmiles":"COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1","inchiKey":"HVXKQKFEHMGHSL-QKDCVEJESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TESEVATINIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["EXEL-7647","KD-019","KD-020","KD019","Tesevatinib","XL647","Xl-647"],"crossReferences":{"drugbank":["DB11973"]},"childChemblIds":["CHEMBL3544982"],"linkedTargets":{"rows":["ENSG00000146648","ENSG00000196411","ENSG00000141736"],"count":3},"linkedDiseases":{"rows":["MONDO_0007254","MONDO_0024880","EFO_0003833","EFO_0003060","EFO_0000519","EFO_1001496","EFO_0000311","Orphanet_731"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL3545048","drugType":"Small molecule","blackBoxWarning":false,"name":"AMG-319","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AMG319","Amg-319","J3.391.906I"],"linkedTargets":{"rows":["ENSG00000171608"],"count":1},"linkedDiseases":{"rows":["EFO_0000095","EFO_0000403","EFO_1001469","EFO_0000181","EFO_0000311"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL3545227","drugType":"Small molecule","blackBoxWarning":false,"name":"NGD-8243","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MK-2295","MK-2295-005","Ngd-8243"],"linkedTargets":{"rows":["ENSG00000196689"],"count":1},"linkedDiseases":{"rows":["EFO_0003843"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3622821","canonicalSmiles":"CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12","inchiKey":"WYQFJHHDOKWSHR-MNOVXSKESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"UPADACITINIB","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Rinvoq"],"synonyms":["ABT-494","Upadacitinib","Upadacitinib anhydrous","Upadacitinib hemihydrate"],"crossReferences":{"DailyMed":["upadacitinib"],"drugbank":["DB15091"]},"childChemblIds":["CHEMBL3707269"],"linkedTargets":{"rows":["ENSG00000096968","ENSG00000162434","ENSG00000105639","ENSG00000105397"],"count":4},"linkedDiseases":{"rows":["EFO_1001209","EFO_0000729","EFO_0000685","EFO_1000710","EFO_0002690","EFO_0003898","EFO_0003778","EFO_0004208","EFO_0000274","EFO_0000540","EFO_0000384","EFO_0002609"],"count":12},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for rheumatoid arthritis and immune system disease and has 10 investigational indications."}
{"id":"CHEMBL371405","canonicalSmiles":"C[C@@]12OC(=O)[C@]1([C@@H](O)[C@@H]1C=CCCC1)NC(=O)[C@@H]2CCCl","inchiKey":"NGWSFRIPKNWYAO-SHTIJGAHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MARIZOMIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Marizomib","NPI-0052","Salinosporamide a"],"crossReferences":{"Wikipedia":["Salinosporamide_A"],"drugbank":["DB11762"],"chEBI":["48045"]},"linkedTargets":{"rows":["ENSG00000136930","ENSG00000100902","ENSG00000100804","ENSG00000106588","ENSG00000277791","ENSG00000041357","ENSG00000222028","ENSG00000154611","ENSG00000240065","ENSG00000204264","ENSG00000126067","ENSG00000101182","ENSG00000100567","ENSG00000143106","ENSG00000129084","ENSG00000205220","ENSG00000008018","ENSG00000142507","ENSG00000159377"],"count":19},"linkedDiseases":{"rows":["EFO_0000574","EFO_0001378","MONDO_0016700","EFO_1000028","EFO_0000519","EFO_0000311"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL38885","canonicalSmiles":"C[C@@H](CC(=O)O)[C@H](N)C(=O)O","inchiKey":"FHJNAFIJPFGZRI-UCORVYFPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL38885","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01898"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3975522","canonicalSmiles":"CC(C)[C@H](N)C(=O)OCC[C@H](NC(=O)[C@@H]1SCCN1S(=O)(=O)c1ccc(-c2ccccc2)cc1)c1ccc(F)cc1","inchiKey":"UUIBKACUTXYSAK-YCVJPRETSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EBOPIPRANT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ebopiprant","OBE-022","OBE022","Obe022"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL406050","canonicalSmiles":"CCC(C)SSc1ncc[nH]1","inchiKey":"BPBPYQWMFCTCNG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PX-12","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Px-12"],"crossReferences":{"PubChem":["174006855"],"drugbank":["DB05448"]},"linkedTargets":{"rows":["ENSG00000136810"],"count":1},"linkedDiseases":{"rows":["EFO_0003860","MONDO_0024880"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL406973","canonicalSmiles":"OC[C@@H]1NC[C@H](O)[C@H]1O","inchiKey":"OQEBIHBLFRADNM-YUPRTTJUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL406973","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03411"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL411","canonicalSmiles":"CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1","inchiKey":"RGLYKWWBQGJZGM-ISLYRVAYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIETHYLSTILBESTROL","yearOfFirstApproval":1973,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"]},"tradeNames":["Apstil","Diethylstilbestrol","Distilbene","Stilbestrol","Stilbetin","Stilboesterol","Tampovagan"],"synonyms":["Cyren a","Diethylstilbestrol","Estrobene","Estrogenine","Estromenin","Fonatol","NSC-3070","New-estranol 1","Palestrol","Stilbestro","Stilbestroform","Stilbestrol","Stilboestrol","Synestrin","Synthestrin"],"crossReferences":{"PubChem":["11532921","144209605","144210844","17389919","26747240","26752777"],"Wikipedia":["Diethylstilbestrol"],"drugbank":["DB00255"],"chEBI":["41922"]},"linkedTargets":{"rows":["ENSG00000091831"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0008315"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for neoplasm and has 1 investigational indication. It was withdrawn in United States."}
{"id":"CHEMBL4297216","canonicalSmiles":"Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O","inchiKey":"QAFZLTVOFJHYDF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FEDRATINIB HYDROCHLORIDE","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1287853","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Inrebic"],"synonyms":["Fedratinib hydrochloride","SAR302503A"],"crossReferences":{"DailyMed":["fedratinib%20hydrochloride"]},"linkedTargets":{"rows":["ENSG00000096968","ENSG00000122025"],"count":2},"linkedDiseases":{"rows":["EFO_0002430","HP_0011974"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for primary myelofibrosis and myelofibrosis."}
{"id":"CHEMBL4297267","canonicalSmiles":"CSCO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]12C)C3(C)C","inchiKey":"UBJAHGAUPNGZFF-XOVTVWCYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BMS-184476","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["7-((methylthio)methyl)paclitaxel","7-methylthiomethylpaclitaxel","Bms-184476"],"crossReferences":{"drugbank":["DB12633"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297370","canonicalSmiles":"O=c1cc(NCCCN[C@@H]2CCOc3c(Br)cc(Br)cc32)[nH]c2ccsc12","inchiKey":"NNTYBKTXMKBRFA-CQSZACIVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CRS-3123","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CRS3123","Crs-3123","Crs3123","REP-3123","REP3123"],"crossReferences":{"drugbank":["DB12262"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297574","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"TEPRASIRAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["I5-NP","I5NP","QPI-1002","Qpi-1002","Teprasiran"],"linkedTargets":{"rows":["ENSG00000141510"],"count":1},"linkedDiseases":{"rows":["HP_0001919"],"count":1},"description":"Oligonucleotide drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4297634","drugType":"Small molecule","blackBoxWarning":false,"name":"GADOPICLENOL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Gadopiclenol","P-03277","P03277"],"description":"Small molecule drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL4297675","canonicalSmiles":"CC(=O)OC[C@H](COc1ccc(C(C)(C)c2ccc(OC[C@@H](CCl)OC(C)=O)cc2)cc1)OC(C)=O","inchiKey":"HGHVYYKTOXUQNT-CLJLJLNGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RALANITEN ACETATE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Epi-506","Ralaniten acetate"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297789","drugType":"Unknown","blackBoxWarning":false,"name":"MT-3724","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mt-3724"],"linkedTargets":{"rows":["ENSG00000148303","ENSG00000142937","ENSG00000171863","ENSG00000265681","ENSG00000116251","ENSG00000198755","ENSG00000147403","ENSG00000177954","ENSG00000142534","ENSG00000124614","ENSG00000100316","ENSG00000008988","ENSG00000149806","ENSG00000137154","ENSG00000161016","ENSG00000143947","ENSG00000167526","ENSG00000166441","ENSG00000089157","ENSG00000186468","ENSG00000130255","ENSG00000105372","ENSG00000172809","ENSG00000161970","ENSG00000171858","ENSG00000231500","ENSG00000164587","ENSG00000142676","ENSG00000145425","ENSG00000142541","ENSG00000071082","ENSG00000129824","ENSG00000122406","ENSG00000213741","ENSG00000108298","ENSG00000188846","ENSG00000197958","ENSG00000136942","ENSG00000105640","ENSG00000162244","ENSG00000170889","ENSG00000156738","ENSG00000174444","ENSG00000174748","ENSG00000138326","ENSG00000137818","ENSG00000110700","ENSG00000083845","ENSG00000131469","ENSG00000122026","ENSG00000144713","ENSG00000198918","ENSG00000109475","ENSG00000168028","ENSG00000145592","ENSG00000147604","ENSG00000198242","ENSG00000108107","ENSG00000115268","ENSG00000114391","ENSG00000089009","ENSG00000063177","ENSG00000182774","ENSG00000198034","ENSG00000241343","ENSG00000149273","ENSG00000182899","ENSG00000125691","ENSG00000163682","ENSG00000233927","ENSG00000112306","ENSG00000134419","ENSG00000197756","ENSG00000118181","ENSG00000105193","ENSG00000140988","ENSG00000197728","ENSG00000229117","ENSG00000156482"],"count":79},"linkedDiseases":{"rows":["EFO_0000095","EFO_0004289","EFO_0000403","EFO_0005952"],"count":4},"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4298025","drugType":"Antibody","blackBoxWarning":false,"name":"ZENOCUTUZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MCLA-128","MCLA128","Mcla 128","Mcla-128","Zenocutuzumab"],"linkedTargets":{"rows":["ENSG00000065361","ENSG00000141736"],"count":2},"linkedDiseases":{"rows":["MONDO_0007254"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4298070","drugType":"Unknown","blackBoxWarning":false,"name":"PROGRAMMED CELL DEATH 1 LIGAND 1","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["B7 homolog 1","B7-h1","Cd-274","Cd274","Pd-l1","Programmed cell death 1 ligand 1","Programmed death ligand 1"],"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL4301078","drugType":"Small molecule","blackBoxWarning":false,"name":"AMMONIUM TETRATHIOMOLYBDATE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL3775741"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4302089","canonicalSmiles":"OC1CN(CCCOCCc2ccc3sccc3c2)C1","inchiKey":"HQNACSFBDBYLJP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"T-817","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Edonerpic","J2.972.359A"],"crossReferences":{"drugbank":["DB05938"]},"childChemblIds":["CHEMBL4297438"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL431698","canonicalSmiles":"Oc1ccc(-c2cc3ccc(O)cc3s2)cc1","inchiKey":"MDGWZLQPNOETLH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RALOXIFENE CORE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08773"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL442565","canonicalSmiles":"CC1=CCC2CC1C2(C)C","inchiKey":"GRWFGVWFFZKLTI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ALPHA-PINENE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[".alpha.-pinene","Acintene a","Alfa-pinene","Alpha-pinene","FEMA NO. 2902","Leavo-95","NSC-7727","PC-500","PC-500(TERPENE)","Sylvapine a"],"crossReferences":{"PubChem":["144207306","17389183"],"drugbank":["DB15573"],"chEBI":["36740"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL445647","canonicalSmiles":"CC(C)CC(=O)C(=O)O","inchiKey":"BKAJNAXTPSGJCU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"2-Oxoisohexanoate","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2-Oxoisohexanoate","alpha-Ketoisocaproate","alpha-Oxoisohexanoate"],"crossReferences":{"Wikipedia":["Alpha-Ketoisocaproic_acid"],"drugbank":["DB03229"],"chEBI":["48430"]},"childChemblIds":["CHEMBL2142054","CHEMBL2361069"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL446452","canonicalSmiles":"c1ccc2c(Cc3c[nH]c4ccccc34)c[nH]c2c1","inchiKey":"VFTRKSBEFQDZKX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ARUNDINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["1,1-Bis(3'-Indolyl)Methane","3,3'-Diindolylmethane","3,3-Diindolylmethane","Arundine","Diindolylmethane"],"crossReferences":{"PubChem":["174007202","26749354","26753756","26753757","26753758","529850"],"Wikipedia":["3,3%27-Diindolylmethane"],"drugbank":["DB11875"],"chEBI":["50182"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4594251","canonicalSmiles":"CS(=O)(=O)O.CS(=O)(=O)O.Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1","inchiKey":"QQDRLKRHJOAQDC-FBHGDYMESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NETARSUDIL DIMESYLATE","yearOfFirstApproval":2017,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL4594250","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Rhopressa"],"synonyms":["AR-13324","Netarsudil dimesylate","Netarsudil mesilate","Netarsudil mesylate"],"crossReferences":{"DailyMed":["netarsudil%20dimesylate","netarsudil%20mesylate"]},"linkedTargets":{"rows":["ENSG00000134318","ENSG00000067900"],"count":2},"linkedDiseases":{"rows":["EFO_0004190","EFO_1001069"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for open-angle glaucoma and ocular hypertension."}
{"id":"CHEMBL46","canonicalSmiles":"Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O","inchiKey":"FELGMEQIXOGIFQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ONDANSETRON","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ondansetron","Zofran","Zofran odt","Zuplenz"],"synonyms":["A04AA01","Desmethylondansetron","EUR-1025","GR-38032","GR-38032F","NSC-757870","Ondansetron","Zofran"],"crossReferences":{"DailyMed":["ondansetron","ondansetron%20hydrochloride"],"PubChem":["124893606","144206599","170464701"],"Wikipedia":["Ondansetron"],"drugbank":["DB00904"],"chEBI":["7773"]},"childChemblIds":["CHEMBL1487310","CHEMBL1201111","CHEMBL3186492"],"linkedTargets":{"rows":["ENSG00000166736"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0003869","EFO_0002610","EFO_1001219","HP_0000989","MONDO_0100342","EFO_0000555","EFO_0020911","MONDO_0007254","EFO_0003768","EFO_0005952","HP_0002018","MONDO_0002046","EFO_0007191","HP_0005184","EFO_0000096","EFO_0003144","HP_0002017","EFO_0008546","HP_0002013","EFO_0004701","MONDO_0007079","EFO_0004242","EFO_0005230","EFO_0005762","EFO_0000616","EFO_0002618","HP_0002094","EFO_0004799","EFO_0005774","EFO_0004210","EFO_0006911","HP_0012532","HP_0011110","EFO_0003843","HP_0002315","EFO_0006912","MONDO_0008315","EFO_0000311","HP_0000738","HP_0001082","EFO_1001463","EFO_0001061","Orphanet_79292","MONDO_0021148","EFO_0011023","EFO_0000764","EFO_0004888","EFO_0005611","MONDO_0043510","EFO_0000691","EFO_0005251","EFO_0007386"],"count":53},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 7 approved and 33 investigational indications."}
{"id":"CHEMBL460962","canonicalSmiles":"C[C@@H]1CN(CC2(C(N)=O)CC2)CCN1S(=O)(=O)c1ccc([C@](C)(O)C(F)(F)F)cc1","inchiKey":"YJFULAYRAKPBCY-DYVFJYSZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL460962","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07624"]},"childChemblIds":["CHEMBL3357072"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4650403","drugType":"Unknown","blackBoxWarning":false,"name":"KISSPEPTIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Kiss-1","Kiss-1 metastasis suppressor","Kisspeptin","Metastin"],"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4650514","drugType":"Antibody","blackBoxWarning":false,"name":"BATOCLIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Batoclimab","HBM-9161","HBM9161","HL161BKN","RVT-1401","RVT1401","Rvt-1401"],"linkedTargets":{"rows":["ENSG00000104870"],"count":1},"linkedDiseases":{"rows":["EFO_0007160","EFO_1001466","EFO_1001264","EFO_0004991"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL471036","canonicalSmiles":"c1ccc2cc(COC3CCNCC3)ccc2c1","inchiKey":"MJJDYOLPMGIWND-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LITOXETINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Litoxetine"],"crossReferences":{"Wikipedia":["Litoxetine"],"drugbank":["DB15038"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL471498","canonicalSmiles":"O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1","inchiKey":"WPGGHFDDFPHPOB-BBWFWOEESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MITIGLINIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mitiglinide"],"crossReferences":{"Wikipedia":["Mitiglinide"],"drugbank":["DB01252"]},"childChemblIds":["CHEMBL1603301"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL485961","canonicalSmiles":"CCc1nc(N)nc(N)c1C#CCc1cc(OC)ccc1OC","inchiKey":"NNFDQABYXZBKRK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL485961","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08234"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL489095","canonicalSmiles":"C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1","inchiKey":"RZKDEGZIFSJVNA-IBGZPJMESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CAMICINAL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Camicinal","GSK-962040","GSK-962040B","GSK962040","GSK962040B","Gsk962040"],"crossReferences":{"drugbank":["DB12567"]},"childChemblIds":["CHEMBL489679"],"linkedTargets":{"rows":["ENSG00000102539"],"count":1},"linkedDiseases":{"rows":["EFO_1000948"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL498623","canonicalSmiles":"O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)Nc1ccc([123I])cc1)C(=O)O)C(=O)O","inchiKey":"LFEGKCKGGNXWDV-NKNRFTOXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MIP-1095 I-123","maximumClinicalTrialPhase":1,"parentId":"CHEMBL456029","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(123i)mip 1095","(123i)mip-1095","123-i-mip-1095","Mip-1095 i-123"],"crossReferences":{"drugbank":["DB12994"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL499","canonicalSmiles":"CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1","inchiKey":"BLJRIMJGRPQVNF-JTQLQIEISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TIMOLOL","yearOfFirstApproval":1978,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Betim","Betimol","Blocadren","Glau-opt","Glaucol","Nyogel","Timolol","Timoptic","Tiopex"],"synonyms":["Blocadren","Istalol","Timolol","Timolol anhydrous","Timolol hemihydrate","Timoptic","Timoptic-XE"],"crossReferences":{"DailyMed":["timolol","timolol%20maleate"],"PubChem":["104171325","11111904","11112709","11113334","144204165","170465062","90341807"],"Wikipedia":["Timolol"],"drugbank":["DB00373"],"chEBI":["9599"]},"childChemblIds":["CHEMBL1200870"],"linkedTargets":{"rows":["ENSG00000169252","ENSG00000043591"],"count":2},"linkedDiseases":{"rows":["EFO_0004190","EFO_1001069","EFO_0004683","EFO_1000879","EFO_0000756","EFO_1000809","EFO_0000319","EFO_0000666","EFO_1001923","EFO_0000546","MONDO_0005277","EFO_0003966","EFO_1001022","Orphanet_774","EFO_0000516","EFO_0009321","EFO_1000635","EFO_0004235"],"count":18},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 4 approved and 12 investigational indications."}
{"id":"CHEMBL523367","canonicalSmiles":"COc1cc(C(C#N)(CCCN(C)CCc2ccccc2)C(C)C)cc(OC)c1OC","inchiKey":"IERWCEALNGTKIK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METHOXYVERAPAMIL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(+/-)-Methoxyverapamil","D-600","DL-D-600","Gallopamil","LU-30-029","Methoxyverapamil"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL545315","canonicalSmiles":"C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1.Cl.Cl","inchiKey":"JZZFDCXSFTVOJY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CANERTINIB DIHYDROCHLORIDE","maximumClinicalTrialPhase":3,"parentId":"CHEMBL31965","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CI-1033","Canertinib dihydrochloride","Canertinib hydrochloride","PD-0183805","PD-0183805-002B","PD-183805","SN-26606"],"linkedTargets":{"rows":["ENSG00000146648","ENSG00000178568","ENSG00000141736"],"count":3},"linkedDiseases":{"rows":["EFO_0003869","MONDO_0021117","EFO_0003060"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL553426","canonicalSmiles":"CC[C@@H](N)C(=O)O","inchiKey":"QWCKQJZIFLGMSD-GSVOUGTGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"(R)-2-Aminobutanoic Acid","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(R)-2-Aminobutanoic Acid"],"crossReferences":{"drugbank":["DB04454"],"chEBI":["28797"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL573887","canonicalSmiles":"CNC(=O)[C@@H](NC(=O)[C@H](OCc1ccccc1)[C@H](O)[C@@H](O)[C@@H](OCc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O)C(C)C","inchiKey":"VZNNJZGVQVNHCM-CDNLURBZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL573887","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04255"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL574737","canonicalSmiles":"CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O","inchiKey":"PBCZSGKMGDDXIJ-KRUBCLEUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"UCN-01","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["7-hydroxystaurosporine","KRX-0601","KW-2401","NSC-638850","UCN-01","UCN-02","Ucn 01","Ucn-01"],"linkedTargets":{"rows":["ENSG00000154229","ENSG00000065675","ENSG00000123374","ENSG00000135446","ENSG00000171132","ENSG00000126583","ENSG00000105810","ENSG00000166501","ENSG00000163558","ENSG00000140992","ENSG00000115825","ENSG00000149554","ENSG00000067606","ENSG00000163932","ENSG00000027075","ENSG00000184304"],"count":16},"linkedDiseases":{"rows":["EFO_1000419","EFO_0002938","MONDO_0044964","EFO_0000756","MONDO_0007254","MONDO_0003196","EFO_0000209","MONDO_0002087","MONDO_0003541","EFO_0000565","MONDO_0001056","MONDO_0002158","EFO_1001013","EFO_1000044","EFO_0000339","EFO_0006352","MONDO_0002974","MONDO_0005411","EFO_0000673","EFO_0004193","EFO_0000198","EFO_0000616","MONDO_0001852","MONDO_0002537","EFO_0002618","EFO_0000221","MONDO_0021321","MONDO_0019457","MONDO_0008170","Orphanet_44890","MONDO_0004669","EFO_1001512","MONDO_0007576","EFO_0000223","EFO_0007535","EFO_0000224","EFO_0003060","EFO_0003025","MONDO_0001879","MONDO_0008315","Orphanet_398934","EFO_1000407","MONDO_0044787","EFO_0003028","EFO_0005537","EFO_0000702","EFO_0000574","MONDO_0002367","EFO_0000218","EFO_0003027","MONDO_0044926"],"count":51},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 44 investigational indications."}
{"id":"CHEMBL650","canonicalSmiles":"C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12","inchiKey":"VHRSUDSXCMQTMA-PJHHCJLFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METHYLPREDNISOLONE","yearOfFirstApproval":1957,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Medrol","Medrone","Methylprednisolone"],"synonyms":["J3.872E","Methylprednisolone","NSC-19987","U-67,590A"],"crossReferences":{"DailyMed":["methylprednisolone"],"PubChem":["144203927","144212335","170465051","56424125","82706","855789"],"Wikipedia":["Methylprednisolone"],"drugbank":["DB00959"],"chEBI":["6888"]},"childChemblIds":["CHEMBL1200844"],"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["Orphanet_64739","EFO_0010822","EFO_1001178","EFO_0007486","MONDO_0100130","EFO_0000756","EFO_0004278","MONDO_0002959","EFO_0005952","EFO_1001345","HP_0011868","EFO_1001909","HP_0011950","EFO_0003914","HP_0100543","EFO_0003103","EFO_0002690","EFO_0003884","MONDO_0004976","EFO_0004991","EFO_0000198","MONDO_0013730","EFO_0009012","HP_0012532","EFO_0001642","EFO_0007537","EFO_1001806","HP_0009926","EFO_0000662","EFO_0000384","MONDO_0008315","Orphanet_95","Orphanet_567","HP_0002027","GO_0007568","EFO_1001365","MONDO_0044889","EFO_1000391","EFO_0003032","EFO_0003957","MONDO_0016226","EFO_0000574","MONDO_0004979","EFO_0004256","EFO_0000341","EFO_0001378","Orphanet_84","EFO_0003086","EFO_0007405","EFO_0007498","MONDO_0007254","EFO_0000255","HP_0004448","EFO_1000637","MONDO_0002135","HP_0002829","MONDO_0002158","EFO_1001254","MONDO_0005180","Orphanet_77260","MONDO_0017287","EFO_0000196","EFO_0004143","EFO_0007208","EFO_0004826","EFO_0000183","EFO_0000616","EFO_0000694","EFO_0003898","EFO_0000403","EFO_0003929","MONDO_0000870","EFO_0003843","EFO_0004599","EFO_0007149","EFO_0000684","EFO_0005297","Orphanet_238510","EFO_1001947","MONDO_0018906","EFO_0000557","EFO_0007167","MONDO_0005178","EFO_0009492","EFO_0003956","EFO_0000729","EFO_0003869","EFO_1001139","EFO_1000905","EFO_0003777","Orphanet_309015","EFO_1000809","MONDO_0000956","EFO_0009373","EFO_1001919","EFO_0000540","MONDO_0100062","EFO_0000565","EFO_0000309","EFO_0004251","EFO_0007448","EFO_0007160","MONDO_0015540","EFO_1001176","EFO_0007332","EFO_0005761","EFO_0004145","EFO_0000220","MONDO_0008170","EFO_1001466","EFO_0004194","MONDO_0044881","EFO_1000784","HP_0001873","MP_0001845","EFO_0003840","MONDO_0100096","EFO_0002428","MONDO_0009348","EFO_0006862","Orphanet_282","EFO_1000965","MONDO_0015686","EFO_1001435","MONDO_0044887","EFO_0003778","EFO_0000274","EFO_0000209","HP_0001915","EFO_0007295","EFO_0004246","MONDO_0005277","Orphanet_70589","EFO_0004254","EFO_1001801","Orphanet_309144","EFO_0007224","MONDO_0020743","HP_0002015","EFO_0000717","EFO_0010580","EFO_0009609","EFO_0000685","HP_0002140","EFO_0003894","EFO_1000941","EFO_0003060","EFO_0000311","EFO_0003106","EFO_0000211","MONDO_0005301","EFO_0000095","EFO_0000706","MONDO_0020077"],"count":154},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 13 approved and 114 investigational indications."}
{"id":"CHEMBL70586","canonicalSmiles":"CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1","inchiKey":"NYKCGQQJNVPOLU-ONTIZHBOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SPIRADOLINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["U-62066"],"crossReferences":{"PubChem":["144206611","170466255"],"drugbank":["DB12704"]},"childChemblIds":["CHEMBL1256692"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL72434","canonicalSmiles":"CC(C)NC(=N)NO","inchiKey":"OITVEDMMUMUWTL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL72434","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02143"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL726","canonicalSmiles":"OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1","inchiKey":"PLDUPXSUYLZYBN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLUPHENAZINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Fluphenazine","NSC-62323","Permitil","Prolixin"],"crossReferences":{"DailyMed":["fluphenazine%20hydrochloride"],"PubChem":["104171155","11111179","11111180","144203697","170465375","26751625","50100242","50104297","57287813","90341540"],"TG-GATEs":["37"],"Wikipedia":["Fluphenazine"],"drugbank":["DB00623"],"chEBI":["5123"]},"childChemblIds":["CHEMBL1200792","CHEMBL1448187"],"linkedTargets":{"rows":["ENSG00000149295"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0005407","EFO_0001378"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for psychosis and has 2 investigational indications."}
{"id":"CHEMBL77562","canonicalSmiles":"O=C(O)c1cc(C(=O)O)cc(C(=O)O)c1","inchiKey":"QMKYBPDZANOJGF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"1,3,5-Benzenetricarboxylic Acid","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["1,3,5-Benzenetricarboxylic Acid","Benzene-1,3,5-Tricarboxylic Acid"],"crossReferences":{"PubChem":["144207215"],"Wikipedia":["Trimesic_acid"],"drugbank":["DB08632"],"chEBI":["46032"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL806","canonicalSmiles":"CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1","inchiKey":"MKXKFYHWDHIYRV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"FLUTAMIDE","yearOfFirstApproval":1989,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Chimax","Drogenil","Eulexin","Flutamide"],"synonyms":["Flutamide","NSC-215876","SCH 13521","SCH-13521"],"crossReferences":{"DailyMed":["flutamide"],"PubChem":["104171162","11111202","11111203","11532925","124880151","124880153","144203705","144209367","144210854","170464921","17388997","174007322","26747365","26747366","26753014","26753015","49675006","50105597","50105598","50105599","50105600","85231055","90341271"],"TG-GATEs":["44"],"Wikipedia":["Flutamide"],"drugbank":["DB00499"],"chEBI":["5132"]},"linkedTargets":{"rows":["ENSG00000169083"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0008170","EFO_0000673","EFO_0000196","EFO_0000313","MONDO_0008315","EFO_0000660","EFO_0001663","Orphanet_418"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 5 approved and 4 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL814","canonicalSmiles":"COCCCC/C(=N\\OCCN)c1ccc(C(F)(F)F)cc1","inchiKey":"CJOFXWAVKWHTFT-XSFVSMFZSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"FLUVOXAMINE","yearOfFirstApproval":1994,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Fluvoxamine","N06AB08"],"crossReferences":{"DailyMed":["fluvoxamine%20maleate"],"PubChem":["104171369","144204388","170464809","26751469","50103976","90340960"],"Wikipedia":["Fluvoxamine"],"drugbank":["DB00176"],"chEBI":["5138"]},"childChemblIds":["CHEMBL1409"],"linkedTargets":{"rows":["ENSG00000108576"],"count":1},"linkedDiseases":{"rows":["EFO_0000694","MONDO_0005090","EFO_0000616","EFO_0004262","MONDO_0002009","HP_0000726","EFO_0003758","EFO_1002014","EFO_1001916","EFO_1001917","EFO_1001892","MONDO_0002050","MONDO_0100096","EFO_0003761","EFO_0004242","EFO_0005230"],"count":16},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 4 approved and 12 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL819","canonicalSmiles":"Cc1onc(-c2ccccc2)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12","inchiKey":"UWYHMGVUTGAWSP-JKIFEVAISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXACILLIN","yearOfFirstApproval":1971,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Oxacillin","Oxazocilline","Prostaphlin"],"crossReferences":{"Wikipedia":["Oxacillin"],"drugbank":["DB00713"],"chEBI":["7809"]},"childChemblIds":["CHEMBL693","CHEMBL3989567"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and is indicated for infection and bacterial disease and has 5 investigational indications."}
{"id":"CHEMBL842","canonicalSmiles":"NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O","inchiKey":"JBMKAUGHUNFTOL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHLOROTHIAZIDE","yearOfFirstApproval":1958,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Chlorothiazide","Diuril","Saluric"],"synonyms":["Chlorothiazide","Chlorthiazide","Hydrochlorothiazide impurity, chlorothiazide-","NSC-25693"],"crossReferences":{"DailyMed":["chlorothiazide","chlorothiazide%20sodium"],"PubChem":["11110950","11110951","144203658","144208170","170465303","17389544","50105505","855976"],"Wikipedia":["Chlorothiazide"],"drugbank":["DB00880"],"chEBI":["3640"]},"childChemblIds":["CHEMBL1200616"],"linkedTargets":{"rows":["ENSG00000070915"],"count":1},"linkedDiseases":{"rows":["EFO_0003777","HP_0003124","EFO_0001645","EFO_0009373","EFO_0000373","EFO_0000319","MONDO_0002462","EFO_0000537","EFO_0003914","HP_0012664","EFO_0003144","EFO_0003884","EFO_0004255","EFO_0000400","MONDO_0005148","EFO_0000668"],"count":16},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1958 and has 8 approved and 5 investigational indications."}
{"id":"CHEMBL87992","canonicalSmiles":"CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc21","inchiKey":"QIALRBLEEWJACW-INIZCTEOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ESLICARBAZEPINE ACETATE","yearOfFirstApproval":2009,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aptiom","Erelib","Pazzul","Stedesa","Zebinix"],"synonyms":["BIA 2-093","BIA-2-093","BIA-2093","Eslicarbazepine acetate","SEP - 0002093","SEP-0002093"],"crossReferences":{"DailyMed":["eslicarbazepine%20acetate"],"PubChem":["29217508","90341297"],"drugbank":["DB09119"],"chEBI":["87016"]},"linkedTargets":{"rows":["ENSG00000185313","ENSG00000153253","ENSG00000183873","ENSG00000136546","ENSG00000144285","ENSG00000169432","ENSG00000168356","ENSG00000007314","ENSG00000136531","ENSG00000196876"],"count":10},"linkedDiseases":{"rows":["EFO_0005762","EFO_1000783","MONDO_0005277","EFO_1000877","EFO_0000474","EFO_0005687","MONDO_0041052","EFO_0004263","EFO_0009963","HP_0001250"],"count":10},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for seizure and epilepsy and has 8 investigational indications."}
{"id":"CHEMBL90568","canonicalSmiles":"COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1O","inchiKey":"MBNGWHIJMBWFHU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIOSMETIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Diosmetin","Diosmetine"],"crossReferences":{"PubChem":["174007266","26756923"],"Wikipedia":["Diosmetin"],"drugbank":["DB11259"],"chEBI":["4630"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL924","canonicalSmiles":"O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O","inchiKey":"XRASPMIURGNCCH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ZOLEDRONIC ACID","yearOfFirstApproval":2001,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aclasta","Reclast","Zerlinda","Zoledronic acid","Zometa"],"synonyms":["AK-156","Anhydrous zoledronic acid","CGP 42446","CGP-42446","CGP-42446A","NSC-721517","Zoladrona acid mylan","Zoledronate","Zoledronate hydrate","Zoledronic","Zoledronic acid","Zoledronic acid accord","Zoledronic acid anhydrous","Zoledronic acid hydrate","Zoledronic acid medac","Zoledronic acid monohydrate","Zoledronic acid teva","Zometa"],"crossReferences":{"DailyMed":["zoledronic%20acid"],"PubChem":["144205292","174006914","29215499"],"Wikipedia":["Zoledronic_acid"],"drugbank":["DB00399"],"chEBI":["46557"]},"childChemblIds":["CHEMBL3989655","CHEMBL4303669","CHEMBL4746555","CHEMBL2103912"],"linkedTargets":{"rows":["ENSG00000160752"],"count":1},"linkedDiseases":{"rows":["EFO_0003869","EFO_0000637","EFO_0000681","EFO_1001919","Orphanet_848","EFO_0005952","EFO_1001147","EFO_0000228","EFO_1001152","EFO_0000333","HP_0000938","EFO_0003931","EFO_0000588","EFO_0000564","MONDO_0002974","EFO_1000786","MONDO_0020732","EFO_0000182","MONDO_0008903","HP_0003419","EFO_0009870","EFO_0001416","Orphanet_740","EFO_0004260","MONDO_0008315","EFO_0001663","EFO_0009708","EFO_0000432","EFO_0001378","EFO_0003922","EFO_1001998","MONDO_0044903","EFO_0003820","Orphanet_232","EFO_0001365","MONDO_0015686","MONDO_0007254","Orphanet_586","EFO_0004252","EFO_0003882","MONDO_0021165","EFO_0002430","EFO_1000044","EFO_1001996","EFO_0000673","EFO_0000196","EFO_0000685","EFO_0004261","Orphanet_666","EFO_0003843","EFO_0003060","EFO_0000621","EFO_0006738","MONDO_0002171","EFO_0003863","EFO_0003854","EFO_0000174","EFO_0000649","EFO_0000764","MONDO_0002367","MONDO_0024880","EFO_0004259","EFO_0000691"],"count":63},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 12 approved and 43 investigational indications."}
{"id":"CHEMBL9352","canonicalSmiles":"O=C1C[C@@H](c2ccc(O)cc2)Oc2cc(O)cc(O)c21","inchiKey":"FTVWIRXFELQLPI-ZDUSSCGKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NARINGENIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-11855"],"crossReferences":{"PubChem":["11112355","11113265","22405473"],"Wikipedia":["Naringenin"],"drugbank":["DB03467"],"chEBI":["17846"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL936","canonicalSmiles":"OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1","inchiKey":"OGAKLTJNUQRZJU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIPHENIDOL","yearOfFirstApproval":1967,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Vontrol"],"synonyms":["Difenidol","Difenidol hydrochloride","Diphenidol","SK&F 478","SK&F-478","SK-478","Vontrol"],"crossReferences":{"PubChem":["11112531","144206624","170465280","50100475"],"Wikipedia":["Diphenidol"],"drugbank":["DB01231"],"chEBI":["4638"]},"childChemblIds":["CHEMBL2105784","CHEMBL1529"],"linkedTargets":{"rows":["ENSG00000168539"],"count":1},"linkedDiseases":{"rows":["EFO_0006862","HP_0002321"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1967."}
{"id":"CHEMBL972","canonicalSmiles":"C#CCN(C)[C@H](C)Cc1ccccc1","inchiKey":"MEZLKOACVSPNER-GFCCVEGCSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"SELEGILINE","yearOfFirstApproval":1989,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Eldepryl","Emsam","Zelapar"],"synonyms":["Eldepryl","L-selegiline","Selegiline","Zelapar"],"crossReferences":{"DailyMed":["selegiline","selegiline%20hydrochloride"],"PubChem":["11113910","26752066"],"Wikipedia":["Selegiline"],"drugbank":["DB01037"],"chEBI":["9086"]},"childChemblIds":["CHEMBL1200904"],"linkedTargets":{"rows":["ENSG00000069535"],"count":1},"linkedDiseases":{"rows":["EFO_0007191","MONDO_0005090","EFO_0002610","MONDO_0002050","EFO_0000289","MONDO_0002009","HP_0012076","MONDO_0005180","MONDO_0004975","EFO_0000673","EFO_0003768","EFO_0003761","EFO_0004701"],"count":13},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 9 investigational indications. This drug has a black box warning from the FDA."}
